These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical and Molecular Aspects of Vitiligo Treatments. Bishnoi A; Parsad D Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783663 [TBL] [Abstract][Full Text] [Related]
3. The enigma and challenges of vitiligo pathophysiology and treatment. Abdel-Malek ZA; Jordan C; Ho T; Upadhyay PR; Fleischer A; Hamzavi I Pigment Cell Melanoma Res; 2020 Nov; 33(6):778-787. PubMed ID: 32198977 [TBL] [Abstract][Full Text] [Related]
4. Vitiligo Pathogenesis and Emerging Treatments. Rashighi M; Harris JE Dermatol Clin; 2017 Apr; 35(2):257-265. PubMed ID: 28317534 [TBL] [Abstract][Full Text] [Related]
5. Research progress of vitiligo repigmentation: from oxidative stress to autoimmunity. Yu T; Wu Y; Lu Z Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):147-151. PubMed ID: 38678613 [TBL] [Abstract][Full Text] [Related]
6. The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios. Tawfik YM; Abd Elazim NE; Abdel-Motaleb AA; Mohammed RAA; Tohamy AMA J Cosmet Dermatol; 2019 Apr; 18(2):638-646. PubMed ID: 30280485 [TBL] [Abstract][Full Text] [Related]
7. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? Xie H; Zhou F; Liu L; Zhu G; Li Q; Li C; Gao T J Dermatol Sci; 2016 Jan; 81(1):3-9. PubMed ID: 26387449 [TBL] [Abstract][Full Text] [Related]
8. Vitiligo: Mechanisms of Pathogenesis and Treatment. Frisoli ML; Essien K; Harris JE Annu Rev Immunol; 2020 Apr; 38():621-648. PubMed ID: 32017656 [TBL] [Abstract][Full Text] [Related]
9. Vitiligo. Ezzedine K; Eleftheriadou V; Whitton M; van Geel N Lancet; 2015 Jul; 386(9988):74-84. PubMed ID: 25596811 [TBL] [Abstract][Full Text] [Related]
10. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Liu LY; Strassner JP; Refat MA; Harris JE; King BA J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882 [TBL] [Abstract][Full Text] [Related]
11. Vitiligo: Mechanistic insights lead to novel treatments. Frisoli ML; Harris JE J Allergy Clin Immunol; 2017 Sep; 140(3):654-662. PubMed ID: 28778794 [TBL] [Abstract][Full Text] [Related]
12. Vitiligo: A Review. Bergqvist C; Ezzedine K Dermatology; 2020; 236(6):571-592. PubMed ID: 32155629 [TBL] [Abstract][Full Text] [Related]
13. Vitiligo: An Update on Pathophysiology and Treatment Options. Speeckaert R; van Geel N Am J Clin Dermatol; 2017 Dec; 18(6):733-744. PubMed ID: 28577207 [TBL] [Abstract][Full Text] [Related]
14. Vitiligo: pathogenetic hypotheses and targets for current therapies. Guerra L; Dellambra E; Brescia S; Raskovic D Curr Drug Metab; 2010 Jun; 11(5):451-67. PubMed ID: 20540698 [TBL] [Abstract][Full Text] [Related]
16. Translational Research in Vitiligo. Katz EL; Harris JE Front Immunol; 2021; 12():624517. PubMed ID: 33737930 [TBL] [Abstract][Full Text] [Related]
17. Repigmentation of vitiligo-associated leukotrichia after autologous, non-cultured melanocyte-keratinocyte transplantation. Al Jasser MI; Ghwish B; Al Issa A; Mulekar SV Int J Dermatol; 2013 Nov; 52(11):1383-6. PubMed ID: 23834588 [TBL] [Abstract][Full Text] [Related]
18. Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo. Wang Y; Li S; Li C Clin Rev Allergy Immunol; 2021 Dec; 61(3):299-323. PubMed ID: 34283349 [TBL] [Abstract][Full Text] [Related]
19. Repigmentation through Melanocyte Regeneration in Vitiligo. Birlea SA; Goldstein NB; Norris DA Dermatol Clin; 2017 Apr; 35(2):205-218. PubMed ID: 28317529 [TBL] [Abstract][Full Text] [Related]